LogicBio raises $45M in series B

On June 27, gene therapy company LogicBio Therapeutics Inc. (Cambridge, Mass.) raised $45 million in a series B round led by new investor Arix Bioscience. New investors OrbiMed, Edmond de Rothschild Investment Partners, Pontifax and SBI Japan-Israel Innovation Fund participated, as did existing investor OrbiMed Israel Partners.

The company was founded in 2015 based on research from co-founder Mark Kay's laboratory at Stanford University. Its GeneRide technology uses homologous recombination to link a therapeutic transgene to a native host promoter to deliver and integrate genetic material without the use of nucleases. The company said the technology minimizes the risk of carcinogenicity caused by added promoters...